title: A trapping ligand antagonist peptide H22-LP inhibition of human cytomegalovirus infection.
abstract: BACKGROUND
  Human cytomegalovirus (HCMV) can cause acute or chronic diseases, especially in immunocompromised patients. Currently, most drugs licensed for the treatment of the herpes virus are nucleoside analogs that have been developed over the past 25 years. Drug resistance, development of drug related toxicity, and side effects limit their clinical use in patients. In a previous study, we found a trapping ligand H22-LP (the conservative sequence is NAHCALL) from a random phage library according to the broad-spectrum trapping receptor H22, which derived from the residue 14-35 near the N-terminal region of receptor US28 on HCMV. Here, the aim was to evaluate the anti-HCMV activity of H22-LP.
  
  
  METHODS
  Antivirus activity of H22-LP on HCMV replication was visualized by fluorescence microscopy. We determined the effects of H22-LP on the expressions of HCMV late protein using q-PCR and Western blot. Comprehensive analysis of the characteristics of H22LP-mediated inhibition of HCMV were quantitatively analyzed by flow cytometry.
  
  
  RESULTS
  H22-LP showed a 65.4% inhibition of viral infection at a concentration of 10 ng, and 50% inhibition at concentrations of 5 ng. The levels of mRNA and proteins were also found to have decreased by H22-LP in a concentration-dependent manner. The mode of antiviral action is based on a block of viral entry cells during HCMV cell adsorption/entry.
  
  
  CONCLUSIONS
  These results demonstrated that H22-LP could inhibit HCMV by direct interaction with the viral particle.
authors.affiliation: Institute of Genomic Medicine, College of Pharmacy, Jinan University, Guangzhou 510632, China.
authors.forename: Wenjun
authors.initials: W
authors.lastname: Shi
authors.affiliation: Institute of Genomic Medicine, College of Pharmacy, Jinan University, Guangzhou 510632, China.
authors.forename: Bo
authors.initials: B
authors.lastname: Xu
authors.affiliation: Institute of Genomic Medicine, College of Pharmacy, Jinan University, Guangzhou 510632, China.
authors.forename: Peng
authors.initials: P
authors.lastname: Tian
authors.affiliation: Institute of Genomic Medicine, College of Pharmacy, Jinan University, Guangzhou 510632, China.
authors.forename: Xiuying
authors.initials: X
authors.lastname: Li
authors.affiliation: Institute of Genomic Medicine, College of Pharmacy, Jinan University, Guangzhou 510632, China. Electronic address: sunhanxiao5@gmail.com.
authors.forename: Hanxiao
authors.initials: H
authors.lastname: Sun
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology*; D015153:Blotting, Western; D003587:Cytomegalovirus / Q000187:drug effects* / Q000502:physiology; D005434:Flow Cytometry; D006801:Humans; D008826:Microbial Sensitivity Tests; D008856:Microscopy, Fluorescence; D010455:Peptides / Q000494:pharmacology*; D014764:Viral Proteins / Q000032:analysis; D014779:Virus Replication / Q000187:drug effects*
chemical_list: D000998:Antiviral Agents; D010455:Peptides; D014764:Viral Proteins
keywords: human cytomegalovirus; peptide; viral G-protein-coupled receptors; viral replication